Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

References

• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S13LP–S28LP. doi:10.2337/dc19-S002
   Google Scholar
• Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. doi:10.1016/S0140-6736(10)60484-9
   PubMed Web of Science ®Google Scholar
• de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539. doi:10.1001/jama.2011.861
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–886. doi:10.1053/j.ajkd.2012.07.005
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi:10.1056/NEJMoa0802743
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:10.1056/NEJMoa0802987
   PubMed Web of Science ®Google Scholar
• Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med. 2008;358(6):580–591. doi:10.1056/NEJMoa0706245
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66(1):255–270. doi:10.1146/annurev-med-051013-110046
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502. doi:10.1038/nrendo.2011.243
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–717. doi:10.1016/S2213-8587(17)30258-9
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–259. doi:10.1161/CIRCULATIONAHA.117.029190
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: a real breakthrough? Diabetes Obes Metab. 2018;20(12):2711–2723. doi:10.1111/dom.13468
   PubMed Web of Science ®Google Scholar
• Fadini GP, Solini A, Manca ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: a multicentre retrospective study. Diabetes Obes Metab. 2019;21(2):252–260. doi:10.1111/dom.13508
   PubMed Web of Science ®Google Scholar
• Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–2506. doi:10.1016/j.jacc.2018.01.085
   PubMed Web of Science ®Google Scholar
• Patorno E, Pawar A, Franklin J, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139(25):2822–2830. doi:10.1161/CIRCULATIONAHA.118.039177
   PubMed Web of Science ®Google Scholar
• Udell J, Yuan Z, Rush T, Sicignano N, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor. Circulation. 2018;137(14):1450–1459. doi:10.1161/CIRCULATIONAHA.117.031227
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi:10.1007/s00125-018-4729-5
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S90LP–S102LP. doi:10.2337/dc19-S009
   Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ. Eur Heart J. 2019:2019. doi:10.1093/eurheartj/ehz486
   Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. doi:10.1016/S2213-8587(19)30249-9
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in Type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739–750. doi:10.1161/CIRCULATIONAHA.119.042007
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. doi:10.1056/NEJMoa1911303
   Google Scholar
• Verma S, Garg A, Yan AT, et al. Effect of Empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39(12):e212LP–e213LP. doi:10.2337/dc16-1312
   Google Scholar
• Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73. doi:10.1186/s12933-018-0717-9
   PubMedGoogle Scholar
• Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132. doi:10.1186/s12933-018-0775-z
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer DC, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with Type 2 diabetes mellitus and coronary artery disease. Circulation. 2019;140(21):1693–1702. doi:10.1161/CIRCULATIONAHA.119.042375
   PubMed Web of Science ®Google Scholar
• Singh JSS, Fathi A, Vickneson K, et al. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97. doi:10.1186/s12933-016-0419-0
   PubMed Web of Science ®Google Scholar
• Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16(1):130. doi:10.1186/s12933-017-0615-6
   PubMedGoogle Scholar
• Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):106. doi:10.1186/s12933-019-0910-5
   PubMedGoogle Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with Type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, E B, et al. Saxagliptin and cardiovascular outcomes in patients with Type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in Type 2 diabetes. N Engl J Med. 2014;371(15):1392–1406. doi:10.1056/NEJMoa1407963
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35(10):2061–2068. doi:10.2337/dc11-2189
   PubMedGoogle Scholar
• Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098–2107. doi:10.1007/s00125-018-4669-0
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Bae JH, Park E-G, Kim S, Kim SG, Hahn S, Kim NH. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009. doi:10.1038/s41598-019-49525-y
   PubMedGoogle Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–274. doi:10.7326/0003-4819-159-4-201308200-00007
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with Type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031. doi:10.1210/jc.2011-2260
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42. doi:10.1186/s12933-017-0529-3
   PubMedGoogle Scholar
• Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–1735. doi:10.2337/dc15-0355
   PubMed Web of Science ®Google Scholar
• Fadini GP, Sciannameo V, Franzetti I, et al. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: a multicentre retrospective study. Diabetes Obes Metab. 2019;21(8):1886–1894. doi:10.1111/dom.13747
   PubMed Web of Science ®Google Scholar
• Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211–220. doi:10.1016/S2213-8587(15)00417-9
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971. doi:10.1038/ki.2013.356
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986. doi:10.1136/bmjopen-2012-001986
   PubMed Web of Science ®Google Scholar
• Olde Engberink RH, Frenkel W, van den Bogaard B, Brewster L, Vogt L, van den Born B. Effects of Thiazide-Type and Thiazide-like Diuretics on cardiovascular events and mortality. Hypertension. 2015;65(5):1033–1040. doi:10.1161/HYPERTENSIONAHA.114.05122
   PubMedGoogle Scholar
• Facchini F. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008–3011. doi:10.1001/jama.1991.03470210076036
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi:10.1056/NEJMra0800885
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404. doi:10.1002/bdd.1909
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZI. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Physiol. 2014;308(2):F77–F83. doi:10.1152/ajprenal.00555.2014
   PubMedGoogle Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462. doi:10.1111/dom.13101
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with Type 2 diabetes. Diabetes. 2016;65(5):1190LP–1195LP. doi:10.2337/db15-1356
   Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. doi:10.1172/JCI72227
   PubMed Web of Science ®Google Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512. doi:10.1038/nm.3828
   PubMed Web of Science ®Google Scholar
• Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43(6):512–520. doi:10.1016/j.diabet.2017.04.002
   PubMed Web of Science ®Google Scholar
• Kuhre RE, Ghiasi SM, Adriaenssens AE, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62(6):1011–1023. doi:10.1007/s00125-019-4849-6
   PubMed Web of Science ®Google Scholar
• Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25–33. doi:10.1111/dom.13012
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60(8):1385–1389. doi:10.1007/s00125-017-4301-8
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. doi:10.1161/CIRCRESAHA.110.223545
   PubMed Web of Science ®Google Scholar
• Ulrich F, Ning X, Huige L. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–735. doi:10.1161/CIRCRESAHA.116.309326
   PubMedGoogle Scholar
• Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66(7):975–987. doi:10.1111/jphp.12223
   PubMed Web of Science ®Google Scholar
• Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9(11):e112394. doi:10.1371/journal.pone.0112394
   PubMed Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777. doi:10.1371/journal.pone.0100777
   PubMed Web of Science ®Google Scholar
• Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. doi:10.1186/s12933-016-0473-7
   PubMed Web of Science ®Google Scholar
• Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148. doi:10.1186/s12933-014-0148-1
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium–glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234(4):3231–3237. doi:10.1002/jcp.26760
   PubMed Web of Science ®Google Scholar
• Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metab Clin Exp. 2018;85:32–37. doi:10.1016/j.metabol.2018.02.002
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with Type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166125. doi:10.1371/journal.pone.0166125
   PubMed Web of Science ®Google Scholar
• Basu D, Huggins L-A, Scerbo D, et al. Mechanism of increased LDL (Low-Density Lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207–2216. doi:10.1161/ATVBAHA.118.311339
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350. doi:10.1056/NEJMra0912063
   PubMed Web of Science ®Google Scholar
• Eriksson JW, Lundkvist P, Jansson P-A, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923–1934. doi:10.1007/s00125-018-4675-2
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with Type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801LP–1808LP. doi:10.2337/dc18-0165
   Google Scholar
• Ito D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with Type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364LP–1372LP. doi:10.2337/dc17-0518
   Google Scholar
• Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20(2):438–442. doi:10.1111/dom.13061
   PubMed Web of Science ®Google Scholar
• Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. 2018;61(10):2155–2163. doi:10.1007/s00125-018-4702-3
   PubMed Web of Science ®Google Scholar
• Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):25–32. doi:10.1016/j.diabet.2015.10.003
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862. doi:10.1111/dom.12127
   PubMed Web of Science ®Google Scholar
• Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8(12):844–847. doi:10.14740/jocmr2760w
   PubMedGoogle Scholar
• Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356LP–363LP. doi:10.2337/dc17-1096
   Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi:10.1016/j.jacc.2009.10.061
   PubMed Web of Science ®Google Scholar
• Zhang J, Bottiglieri T, McCullough PA. The central role of endothelial dysfunction in cardiorenal syndrome. Cardiorenal Med. 2017;7(2):104–117. doi:10.1159/000452283
   PubMed Web of Science ®Google Scholar
• Anderson TJ. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol. 2006;22(Suppl B):72B–80B. doi:10.1016/s0828-282x(06)70990-4
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. doi:10.1186/1475-2840-13-28
   PubMed Web of Science ®Google Scholar
• Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138. doi:10.1186/s12933-017-0621-8
   PubMed Web of Science ®Google Scholar
• Ramirez AJ, Sanchez MJ, Sanchez RA. Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. J Hypertens. 2019;37:3. doi:10.1097/HJH.0000000000001907
   Google Scholar
• Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84. doi:10.1186/s12933-017-0564-0
   PubMedGoogle Scholar
• Tanaka A, Shimabukuro M, Machii N, et al. Effect of empagliflozin on endothelial function in patients with Type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care. 2019;42(10):e159LP–e161LP. doi:10.2337/dc19-1177
   Google Scholar
• Baartscheer A, Schumacher CA, Wust RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–573. doi:10.1007/s00125-016-4134-x
   PubMed Web of Science ®Google Scholar
• Darmellah A, Baetz D, Prunier F, Tamareille S, Rücker-Martin C, Feuvray D. Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto–kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia. 2007;50(6):1335–1344. doi:10.1007/s00125-007-0628-x
   PubMedGoogle Scholar
• Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183. doi:10.1161/JAHA.115.002183
   PubMedGoogle Scholar
• Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722–726. doi:10.1007/s00125-017-4509-7
   PubMed Web of Science ®Google Scholar
• Clancy CE, Chen-Izu Y, Bers DM, et al. Deranged sodium to sudden death. J Physiol. 2015;593(6):1331–1345. doi:10.1113/jphysiol.2014.281204
   PubMedGoogle Scholar
• Kohlhaas M, Liu T, Knopp A, et al. Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation. 2010;121(14):1606–1613. doi:10.1161/CIRCULATIONAHA.109.914911
   PubMed Web of Science ®Google Scholar
• Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549–574. doi:10.1007/s00018-013-1349-6
   PubMed Web of Science ®Google Scholar
• Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310. doi:10.1016/j.freeradbiomed.2017.01.035
   PubMed Web of Science ®Google Scholar
• Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. doi:10.1186/s12933-019-0816-2
   PubMedGoogle Scholar
• Jeong J-W, Jeong MH, Yun KH, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J. 2007;71(4):536–539. doi:10.1253/circj.71.536
   PubMed Web of Science ®Google Scholar
• Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. doi:10.1186/s12933-017-0658-8
   PubMedGoogle Scholar
• Fadini GP, Ciciliot S, Albiero M. Concise review: Perspectives and clinical implications of bone marrow and circulating stem cell defects in diabetes. Stem Cells. 2017;35(1):106–116. doi:10.1002/stem.2445
   PubMedGoogle Scholar
• Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A. Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with Type 2 diabetes. Diabetes Care. 2017;40(1):125LP–131LP. doi:10.2337/dc16-1755
   Google Scholar
• Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in Type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100(7):2666–2672. doi:10.1210/jc.2015-1687
   PubMedGoogle Scholar
• Bonora BM, Cappellari R, Albiero M, Avogaro A, Fadini GP. Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with Type 2 diabetes. J Clin Endocrinol Metab. 2018;103(10):3773–3782. doi:10.1210/jc.2018-00824
   PubMedGoogle Scholar
• Fadini GP, de Kreutzenberg SV, Mariano V, et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab. 2011;13(8):718–725. doi:10.1111/j.1463-1326.2011.01396.x
   PubMed Web of Science ®Google Scholar
• Hess DA, Terenzi DC, Trac JZ, et al. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with Type 2 diabetes mellitus. Cell Metab. 2019;30(4):609–613. doi:10.1016/j.cmet.2019.08.015
   PubMedGoogle Scholar